# Pub. L. 87-781

Pub. L. 87-781 is a public law; it amends 7 sections.

IRI: <https://ontology.bommaritollc.com/id/01a0f06c-d277-745c-b0ca-9efb3d92cc8a>

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [us-public-law 87-781](https://ontology.bommaritollc.com/id/01a0f06c-d279-75dd-8afa-0c65779da162)
- `eli:amends`:
  - [21 U.S.C. 321 Definitions; generally](https://ontology.bommaritollc.com/id/01a0f06c-cc8c-7030-ab68-1def0b197dcb)
  - [21 U.S.C. 331 Prohibited acts](https://ontology.bommaritollc.com/id/01a0f06c-cc92-7163-972f-ca345be44724)
  - [21 U.S.C. 348 Food additives](https://ontology.bommaritollc.com/id/01a0f06c-ccb3-7607-845c-4cd3875abe1f)
  - [21 U.S.C. 351 Adulterated drugs and devices](https://ontology.bommaritollc.com/id/01a0f06c-ccc8-7536-94e4-d8e798dad75a)
  - [21 U.S.C. 352 Misbranded drugs and devices](https://ontology.bommaritollc.com/id/01a0f06c-ccca-77a6-a36b-8f6a7374070e)
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [21 U.S.C. 379e Listing and certification of color additives for foods, drugs, devices, and cosmetics](https://ontology.bommaritollc.com/id/01a0f06c-cd98-7399-b68d-fe6ae17270b5)
- `eli:changes`:
  - [21 U.S.C. 332 Injunction proceedings](https://ontology.bommaritollc.com/id/01a0f06c-cc93-7334-bb4c-f663eaaa66c3)
  - [21 U.S.C. 353 Exemptions and consideration for certain drugs, devices, and biological products](https://ontology.bommaritollc.com/id/01a0f06c-cccb-7545-90e2-a1651be32192)
  - [21 U.S.C. 358 Authority to designate official names](https://ontology.bommaritollc.com/id/01a0f06c-ccf9-704b-8dfc-d48c5f351545)
  - [21 U.S.C. 359 Nonapplicability of subchapter to cosmetics](https://ontology.bommaritollc.com/id/01a0f06c-ccfa-7050-b871-2de2b29477ed)
  - [21 U.S.C. 360 Registration of producers of drugs or devices](https://ontology.bommaritollc.com/id/01a0f06c-ccfb-75a5-8f8d-2899cf8ac727)
  - [21 U.S.C. 372 Examinations and investigations](https://ontology.bommaritollc.com/id/01a0f06c-cd80-719d-a261-d5949128e1c5)
  - [21 U.S.C. 374 Inspection](https://ontology.bommaritollc.com/id/01a0f06c-cd83-7175-9624-79d9d7728390)
  - [21 U.S.C. 381 Imports and exports](https://ontology.bommaritollc.com/id/01a0f06c-cdf5-70c8-b8d2-b17f8ad341e4)
- `prov:wasDerivedFrom`: [evidence from https://www.govinfo.gov/app/details/PLAW-87publ781](https://ontology.bommaritollc.com/id/01a0f06c-d277-745c-b0ca-9efad6af8a30)
- `schema:legislationDate`: 1962-10-10 (xsd:date)
- `schema:legislationIdentifier`: Pub. L. 87-781
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationType`: [public law](https://ontology.bommaritollc.com/vocab/leg/publicLaw)
- `skos:prefLabel`: Pub. L. 87-781

## Elsewhere

- [Source](https://www.govinfo.gov/app/details/PLAW-87publ781) (www.govinfo.gov)

## Pointing here

- Cited by (3; `eli:cites`):
  - [21 CFR 299.4 Established names for drugs.](https://ontology.bommaritollc.com/id/01a0f094-c46b-7708-9cc2-9e52d8aa3652)
  - [21 CFR 310.100 New drug status opinions; statement of policy.](https://ontology.bommaritollc.com/id/01a0f094-c471-779f-bf2e-1cd054a5418d)
  - [21 CFR 314.108 New drug product exclusivity.](https://ontology.bommaritollc.com/id/01a0f094-c4d2-73b4-b98c-50ba30f10af0)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f06c-d277-745c-b0ca-9efb3d92cc8a.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f06c-d277-745c-b0ca-9efb3d92cc8a.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f06c-d277-745c-b0ca-9efb3d92cc8a.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f06c-d277-745c-b0ca-9efb3d92cc8a)
Cite as: Pub. L. 87-781. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f06c-d277-745c-b0ca-9efb3d92cc8a
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
